These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 23659299)

  • 41. [Meningococcal disease in the Netherlands: media hype, but not an epidemic].
    van Furth AM; Zaaijer HL
    Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
    Hogea C; Van Effelterre T; Vyse A
    Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL; Gay NJ; Edmunds WJ
    Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Changing Epidemiology of Meningococcal Disease.
    Cohn A; MacNeil J
    Infect Dis Clin North Am; 2015 Dec; 29(4):667-77. PubMed ID: 26610420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of new vaccines against meningococcal disease.
    Bröker M
    Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
    Sáfadi MA; McIntosh ED
    Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Will booster doses be required for serogroup B meningococcal vaccine?
    McQuaid F; Snape MD
    Expert Rev Vaccines; 2014 Mar; 13(3):313-5. PubMed ID: 24451002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
    Gendrel D
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The epidemiology of meningococcal disease and the impact of vaccines.
    Khatami A; Pollard AJ
    Expert Rev Vaccines; 2010 Mar; 9(3):285-98. PubMed ID: 20218857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of vaccination on meningococcal epidemiology.
    Stefanelli P; Rezza G
    Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.